IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
Rhea-AI Summary
IceCure Medical (Nasdaq: ICCM) signed an exclusive distribution agreement with Scovas Medical for its ProSense® cryoablation systems in the Netherlands, covering breast cancer and interventional oncology. Scovas will initially act as exclusive distributor, with a view to negotiating a longer-term agreement subject to both parties.
According to IceCure, the deal supports market development and clinical education in a country with strong interventional radiology expertise. The Netherlands-hosted, independent multicenter randomized THERMAC trial has advanced to Phase III focusing on cryoablation, after earlier data showed ProSense® achieved the highest complete ablation rate among evaluated thermal ablation techniques, with a 94% success rate, 0% complication rate and 100% treatment tolerance without general anesthesia.
Positive
- Exclusive ProSense® distribution in Netherlands via Scovas Medical for breast cancer and interventional oncology
- THERMAC trial progressed to Phase III in Netherlands with focus on cryoablation
- ProSense® clinical metrics in THERMAC: 94% success rate, 0% complication rate, 100% treatment tolerance without general anesthesia
- ProSense® achieved highest complete ablation rate among evaluated thermal ablation techniques in THERMAC data
Negative
- None.
Market reaction after Netherlands distribution partnership: ICCM -6.96%
Following this news, ICCM has declined 6.96%, reflecting a notable negative market reaction. Argus tracked a peak move of +2.9% during the session. Our momentum scanner has triggered 11 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $2.26. Trading volume is exceptionally heavy at 405.0x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 20 | IRB approval | Positive | -2.8% | West Cancer Center received approval to begin enrolling ChoICE Study patients. |
| Aug 13 | Peer-reviewed publications | Positive | -3.4% | Two publications supported cryoablation for breast cancer treatment de-escalation. |
| Aug 12 | 1H26 earnings report | Neutral | -11.5% | Revenue growth and gross-profit gains accompanied a wider net loss. |
| Aug 6 | Clinical site approval | Positive | -4.0% | Adventist Health Glendale became the first U.S. ChoICE enrollment site. |
| Aug 5 | Earnings date notice | Neutral | +2.6% | The company scheduled its first-half 2026 results release for August 12. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and regulatory announcements were followed by negative 24-hour reactions, including declines of -2.78%, -3.38%, and -4.05%.
Key Terms
cryoablation medical
thermal ablation medical
interventional oncology medical
treatment de-escalation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Agreement expands ProSense® commercialization in
Under the Agreement, Scovas will serve as IceCure's exclusive distributor for ProSense® in
"This exclusive distribution agreement strengthens IceCure's European commercialization strategy and supports broader ProSense® access in
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the
About Scovas Medical
Scovas Medical is an independent medical device distributor and sales agent based in the Netherlands. The company provides distribution and clinical sales support to healthcare professionals across several medical specialties, including interventional radiology, vascular surgery, neurointerventional radiology, interventional cardiology and vascular access.
Investor Contact
Meir Peleg, CFO
investors@icecure-medical.com
+1-888-902-5716
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. For example, the Company is using forward-looking statements when it discusses: the anticipated benefits of the Agreement with Scovas Medical; a further longer-term agreement between the parties; the potential for the Agreement to support broader market access, market development, clinical education and physician access for ProSense® in the Netherlands; the Company's European commercialization strategy; the potential adoption of ProSense® in the Netherlands and other markets; the potential clinical, patient-quality-of-life, cosmetic and healthcare-cost benefits of minimally invasive cryoablation for selected breast cancer patients; the potential of ProSense® to support outpatient-friendly, image-guided oncology procedures; the advancement, design, focus and potential implications of the THERMAC trial, including its Phase III focus on cryoablation; and the potential role of cryoablation in treatment de-escalation for selected patients with early-stage breast cancer.. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/icecure-signs-exclusive-distribution-agreement-for-prosense-cryoablation-systems-in-the-netherlands-302858160.html
SOURCE IceCure Medical